Proteomics of Malignant CellsPresentation Transcript
Puchades, M.; Nilsson, C.L.; Emmett, M.R.; Aldape, K.D.; Ji, Y.; Lang, F.F.; Liu, T.J. and C.A. Conrad. « Proteomic Investigation of Glioblastoma Cell Lines Treated with Wild-Type p53 and Cytotoxic Chemotherapy Demonstrates an Association between Galectin-1 and p53 Expression » J. Proteome Res. (2007), 6, 869-875. Proteomics of Malignant Cells: Discovery of a Clinical Biomarker of Brain Tumor Invasivity In vitro staining of glioblastoma cells after adenovirus therapy Untreated cells stained without (left) and with (center) anti-galectin-1 antibody. After treatment (right) galectin-1 reactivity is greatly reduced. Proteomic analysis of glioblastoma cells after adenovirus therapy Comparison of gels demonstrates a large reduction in galectin-1 in treated (A) cells vs. controls (B) Acknowledgements NSF DMR 0084173, Knut and Alice Wallenberg Foundation (C.L. Nilsson, P.I.), STINT (M.R. Emmett and C.L. Nilsson, co-P.Is), and Celebrate Life Charitable Organization (C.A. Conrad, P.I.) Gliomas are the most common type of primary brain tumor and are characterized by invasivity and resistance to chemotherapy. In collaboration with neuro-oncologists at M.D. Anderson Cancer Center in Houston, Texas, an important factor which promotes tumor invasivity, galectin-1, was identified through proteomic analysis. Current studies in the FT-ICR group focus on the identification of binding partners of galectin-1, while MDACC develops galectin-1 binding drugs for clinical use.